

UNITED STATES PARTMENT OF COMMERCE Patent and Trademark Office

NOTICE OF ALLOWANCE AND ISSUE FEE DUE

HM12/0706

The Law Offices of Imre Balogh 276 Smith School Road Perkasie PA 18944

APPLICATION NO.		FILING DATE,	TOTAL CLAIMS	EXAMINER AND GROUP ART UNIT		DATE MAILED
	09/488,420	01/20/00	020	KIM, V	. 161	4 07/06/00
First Named Applicant	FARRAR,	7	35	USC 154(b) term ext. =	0 Days.	

TITLE OF KAPPA AGONIST ANTI-PRURITIC PHARMACEUTICAL FORMULATIONS AND METHOD OF INVENTION TREATING PRURITUS THEREWITH

ATTY'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	TCH NO. APPLN. TYPE		SMALL ENTITY	FEE DUE	DATE DUE
1 A/B-1006	Div 514-3	320.000	097	UTILIT	ry yes	\$605.00	10/06/00

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED.

THE ISSUE FEE MUST BE PAID WITHIN <u>THREE MONTHS</u> FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED.

HOW TO RESPOND TO THIS NOTICE:

- I. Review the SMALL ENTITY status shown above.
 If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:
 - A. If the status is changed, pay twice the amount of the FEE DUE shown above and notify the Patent and Trademark Office of the change in status, or
 - B. If the status is the same, pay the FEE DUE shown above.

If the SMALL ENTITY is shown as NO:

- A. Pay FEE DUE shown above, or
- B. File verified statement of Small Entity Status before, or with, payment of 1/2 the FEE DUE shown above.
- II. Part B-Issue Fee Transmittal should be completed and returned to the Patent and Trademark Office (PTO) with your ISSUE FEE. Even if the ISSUE FEE has already been paid by charge to deposit account, Part B Issue Fee Transmittal should be completed and returned. If you are charging the ISSUE FEE to your deposit account, section "4b" of Part B-Issue Fee Transmittal should be completed and an extra copy of the form should be submitted.
- III. All communications regarding this application must give application number and batch number.

 Please direct all communications prior to issuance to Box ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

#6/8 10-30-00



Application No. 09/488,420

Applicants)

Farrar et al

Examiner

Vickie Kim

Group Art Unit 1614



All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance and Issue Fee Due or other appropriate communication will be mailed in due course.
This communication is responsive to Examiner's amendt. request filed on June 29, 2000.
The allowed claim(s) is/are 67-86
☐ The drawings filed on are acceptable.
☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been
☐ received.
received in Application No. (Series Code/Serial Number)
received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
*Certified copies not received:
Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).
A SHORTENED STATUTORY PERIOD FOR RESPONSE to comply with the requirements noted below is set to EXPIRE THREE MONTHS FROM THE "DATE MAILED" of this Office action. Failure to timely comply will result in ABANDONMENT of this application. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).
☐ Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL APPLICATION, PTO-152, which discloses that the oath or declaration is deficient. A SUBSTITUTE OATH OR DECLARATION IS REQUIRED.
☐ Applicant MUST submit NEW FORMAL DRAWINGS
☐ because the originally filed drawings were declared by applicant to be informal.
☐ including changes required by the Notice of Draftsperson's Patent Drawing Review, PTO-948, attached hereto or to Paper No
including changes required by the proposed drawing correction filed on, which has been approved by the examiner.
including changes required by the attached Examiner's Amendment/Comment.
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal lettter addressed to the Official Draftsperson.
☐ Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.
Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included.
Attachment(s)
Notice of References Cited, PTO-892
Information Disclosure Statement(s), PTO-1449, Paper No(s)2
□ Notice of Draftsperson's Patent Drawing Review, PTO-948
☐ Notice of Informal Patent Application, PTO-152☒ Interview Summary, PTO-413
Examiner's Comment Regarding Requirement for Deposit of Biological Material
Examiner's Statement of Reasons for Allowance

Art Unit: 1614

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Villacota on June 28, 2000 .

2. The application has/been amended as follows: cancel claims 63-66.

Allowable Subject Matter

3. The following is an examiner's statement of reasons for allowance: WO9503308 teaches a morphinan derivatives which have potent analgesic, antitussive and diuretic effects as highly selective kappa -opioid agonists. EP330469 teaches tetrahydroisoquinoline derivatives as kappa agonists analgesics for the treatment of cerebral ischemia. However it fails to teach or state a method for treating pruritus using the same said compounds. US patent 5,869,521 and 5,760,023 which are claimed as instant application's own priority document, only teach kappa

Art Unit: 1614

agonists is useful in treatment of pruritus. Thus the claimed subject matter is free of prior art and patentably distinct over any prior art in the state.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

- 4. All the pending claims are allowed.
- 5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to *Vickie Kim* whose telephone number is **(703) 305-1675** (Monday-Thursday: 7AM-6PM) and Fax number is **(703)** 308-7924.

Vickie Kim,

Patent examiner

June 30, 2000

William Jarvis

Primary examiner

Art unit 1614